• Home
  • NEW DAY MEDICINE
  • 3 (65) 2024
  • 92 -3 (65) 2024 - N.S. Mamasoliev., G.Zh. Khomidova. - NON-ALCOHOLIC STEATHOEPATITIS – A DISEASE OF CIVILIZATION: NEW PERSPECTIVES AND SOLUTIONS

92 -3 (65) 2024 - N.S. Mamasoliev., G.Zh. Khomidova. - NON-ALCOHOLIC STEATHOEPATITIS – A DISEASE OF CIVILIZATION: NEW PERSPECTIVES AND SOLUTIONS

NON-ALCOHOLIC STEATHOEPATITIS – A DISEASE OF CIVILIZATION: NEW PERSPECTIVES AND SOLUTIONS

N.S. Mamasoliev Andijan State Medical Institute of Uzbekistan Republican Scientific Center for Emergency Medical Care, Andijan

G.Zh. Khomidova Andijan State Medical Institute of Uzbekistan Republican Scientific Center for Emergency Medical Care, Andijan

Z.N. Mamasoliev Andijan State Medical Institute of Uzbekistan Republican Scientific Center for Emergency Medical Care, Andijan

R.R. Kurbonova Andijan State Medical Institute of Uzbekistan Republican Scientific Center for Emergency Medical Care, Andijan

G.R. Adilova Andijan State Medical Institute of Uzbekistan Republican Scientific Center for Emergency Medical Care, Andijan

Resume

In modern sources, non-alcoholic steatohepatitis is presented as fatty hepatosis, correctly reflecting its pathogenetic essence, and it is emphasized as an increasingly widespread disease. The disease is mainly caused by poor diet and lack of physical activity. Also, diabetes, hormonal disorders and genetic diseases, as well as all risk factors of cardiovascular diseases (arterial hypertension, alcohol consumption, smoking, mental stress, less than normal consumption of fruit and vegetable products, age and gender factors, metabolic syndrome, excess body weight , obesity, etc.) are considered to be the initial and/or aggravating causes of the problem of this period - if predictive, preventive or preventive measures are not carried out in time, scientifically based and individualized, this situation will lead to liver inflammation (steatohepatitis) and dysfunction the risk of import remains.

Keywords: non-alcoholic steatohepatitis, predictive, preventive, prophylactic, chronic liver diseases, alcohol consumption, cardiovascular diseases.

First page

495

Last page

500

For citation: N.S. Mamasoliev., G.Zh. Khomidova., Z.N. Mamasoliev., R.R. Kurbonova, G.R. Adilova - NON-ALCOHOLIC STEATHOEPATITIS – A DISEASE OF CIVILIZATION: NEW PERSPECTIVES AND SOLUTIONS//New Day in Medicine 3(65)2024 495-500 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Анисонян А.В., Сандлер Ю.Г., Хайменова Т.Ю., Кейян В.А., Салиев К.Г., Сбикина Е.С. и др. Неалкогольная жировая болезнь печени и сахарный диабет 2-го типа: вопросы диагностики фиброза печени. // Терапевтический архив. 2020;92(8):73–8.
  2. Драпкина, О. М. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования — наблюдения DIREGL01903 / О. М. Драпкина, В. Т. Ивашкин // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. — 2014. — Т. 24, № 4. — С. 32–36.
  3. Ивашкин В.Т., Драпкина О.М., Маев И.В., Трухманов А.С., Блинов Д.В., Пальгова Л.К., Цуканов В.В., Упакова Т.И. Распространенность Неалкогольной жировой болезни печени у пациенов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG2, РЖГГК, 2015, 6, 31-41.
  4. Караман (Денисенко) Ю.К., Новгородцева Т.П., Жукова Н.В., Янькова В.И. Состав фосфолипидов и активность редокс-системы глутатиона печени крыс в условиях пролонгированной высокожировой нагрузки. // Российский физиологический журнал им. И.М. Сеченова. 2012;98(8):1000–1007.
  5. Кытикова О.Ю., Новгородцева Т.П., Денисенко Ю.К., Ковалевский Д.А. Метаболические и генетические детерминанты нарушения липидного обмена при неалкогольной жировой болезни печени // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2020; 30(2): 15-25.
  6. Мамасолиев Н.С., Кац Я.А. Внутренние болезни. Учебник // 000 “Tibbiyot nashriyoti matbaa uyi”. – Тошкент. – 2023. – Б. 66-74.
  7. Новгородцева Т.П., Караман (Денисенко) Ю.К., Жукова Н.В. Модификация состава жирных кислот полярных и нейтральных липидов крови и ткани печени крыс в условиях пролонгированной высокожировой диеты. // Биомедицинская химия. 2013;59(6):644–654.
  8. Харари Ю.Н. Homo Deus. Краткая история будущего [пер. сангл. А.Андреева] – М. – 2019. – Б. 434-498. @ssvuz [@ssvmatbuotkotibi]. Facebook [instagram].
  9. Arab J.P., Arrese M., Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. // Annu Rev Pathol. 2018;13:321–350. DOI: 10.1146/annurevpathol-020117-043617.
  10. Auffray C., Charron D., Hood L. Predictiv, preventive, personalized and participatory medicine: back and the future // Genom Med. – 2010. – Vol. 26. - №2 (8). – P. 51-58.
  11. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with nonalcoholic fatty liver disease // World J Gastroenterol 2014; 20:1724-1745.
  12. Bhatia L.S., Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver diasease: a new and important cardiovascular risk factor? // Eur Heart J 2012; 33:1190-1200.
  13. Bril F., Cusi K. Management of non-alcoholic fatty liver disease in patients with type 2 diabetes: A Call To Action. // Diabetes Care. 2017;40(3):419–430. DOI: 10.2337/dc16-1787.
  14. Castro L.F.C., Tocher D.R., Monroig O. Long-chain polyunsaturated fatty acid biosynthesis in chordates: in sights into the evolution of fads and elovl gene repertoire. // Prog. Lipid Res. 2016;62:25–40. DOI: 10.1016/j.plipres.2016.01.001
  15. Dasarathy S., Dasarathy J., Khiyami. Double-blind randomized placebocontrolled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. // J. Clin. Gastroenterol. 2015;49:137–144. DOI: 10.1097/MCG.0000000000000099.
  16. E lamparast T., Tandon P., Raman M. Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease. // Nutrients. 2017;9(8). DOI:10.3390/nu9080800.
  17. Gillberg L., Perfilyev A., Brons C., Thomasen M., Grunnet L.G., Volkov P., et al. Adipose tissue transcriptomics and epigenomics in low birthweight men and controls: role of high-fat overfeeding. // Diabetologia. 2016;59(4):799–812. DOI: 10.1007/s00125-015-3852-9.
  18. Gonzalez-Bengtsson A., Asadi A., Hui Gao, Dahlman-Wright K., Jacobsson A. Estrogen Enhances the Expression of the Polyunsaturated Fatty Acid Elongase Elovl2 via erα in Breast Cancer Cells. РLoS One. 2016;11(10):e0164241. DOI: 10.1371/journal.pone.0164241.
  19. Howard T.D., Mathias R.A., Seeds M.C., Herrington D.M., Hixson J.E., Shimmin L.C., et al. DNA methylation in an enhancer region of the FADS cluster is associated with FADS activity in human liver. // PLoS One. 2014;9(5):e97510. DOI: 10.1371/journal.pone.0097510.
  20. Jump D.B., Lytle K.A., Depner C.M., Tripathy S. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. // Pharmacol Ther. 2018;181:108–125. DOI: 10.1016/j.pharmthera.

    file

    download